Oligomeric compounds for the modulation HIF-1α expression

Details Oligomeric compounds for the modulation HIF-1α expression Oligomeric compounds for the modulation HIF-1α expression

2003-04-04

2010-06-15

Chong, Kimberly (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S024310, C536S024100, C435S006120, C435S325000, C435S375000, C514S04400A

Reexamination Certificate

active

07737264

ABSTRACT:
Oligonucleotides directed against the hypoxia-inducible factor-1α (HIF-1α) gene are provided for modulating the expression of HIF-1α. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1α. Methods of using these compounds for modulation of HIF-1α expression and for the treatment of diseases associated with the hypoxia-inducible factor-1α are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.

REFERENCES:
patent: 4857653 (1989-08-01), Colin et al.
patent: 5227400 (1993-07-01), Holton et al.
patent: 5248796 (1993-09-01), Chen et al.
patent: 5250683 (1993-10-01), Holton et al.
patent: 5254580 (1993-10-01), Chen et al.
patent: 5272171 (1993-12-01), Yasutsugu et al.
patent: 5278324 (1994-01-01), Kingston et al.
patent: 5595760 (1997-01-01), Cherif-Cheikh
patent: 5672659 (1997-09-01), Shalaby et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5882914 (1999-03-01), Semenza
patent: 5994076 (1999-11-01), Chenchik et al.
patent: 6030954 (2000-02-01), Wu
patent: 6706505 (2004-03-01), Han et al.
patent: 6770748 (2004-08-01), Imanishi et al.
patent: 6821724 (2004-11-01), Mittman et al.
patent: 2003/0032794 (2003-02-01), Koch et al.
patent: 2004/0002473 (2004-01-01), Kurreck et al.
patent: 2004/0220393 (2004-11-01), Ward et al.
patent: 0 253 739 (1989-10-01), None
patent: WO 92/09589 (1992-06-01), None
patent: WO 93/18210 (1993-09-01), None
patent: WO/96/39426 (1996-12-01), None
patent: WO 99/14226 (1999-03-01), None
patent: WO/99/48916 (1999-09-01), None
patent: WO 99/49065 (1999-09-01), None
patent: WO 00/56746 (2000-09-01), None
patent: WO 00/56748 (2000-09-01), None
patent: WO 00/64262 (2000-11-01), None
patent: WO 00/64262 (2000-11-01), None
patent: WO 00/66604 (2000-11-01), None
patent: WO00/76497 (2000-12-01), None
patent: WO 00/78341 (2000-12-01), None
patent: WO 01/25248 (2001-04-01), None
patent: WO 02/28875 (2002-04-01), None
patent: WO 02/34291 (2002-05-01), None
patent: WO 02/094250 (2002-11-01), None
patent: WO 02/099104 (2002-12-01), None
patent: WO 03/006475 (2003-01-01), None
patent: WO 03/085110 (2003-10-01), None
patent: WO 03/095467 (2003-11-01), None
patent: WO 2004/042024 (2004-05-01), None
patent: WO 2004/046160 (2004-06-01), None
patent: WO 2004/069991 (2004-08-01), None
patent: WO 2004/069992 (2004-08-01), None
Koshkin et al. LNA (Locked Nucleic Acids): Synthesis of the Adenine, Cytosine, Guanine, 5-Methylcytosine, Thymine and Uracil Bicyclonucleoside Monomers, Oligomerisation, and Unprecedented Nucleic Acid Recognition. Tetrahedron 1998, vol. 54: 3607-3630. Elsevier Science Ltd.
Kurreck et al. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Research 2002, Vo. 30. No. 9: 1911-1918.
Hoeg et al.,Proceedings of the Annual Meeting of the American Association for Cancer Research, vol. 43, pp. 962 (2002) Database No. XP-001154041.
Kang et al.,Circulation, American Heart Associatio, vol. 104, No. 17, Suppl., pp. 1157 (2001), Database No. XP009015505.
L'Allemain,Bull. Cancer, vol. 89, No. 3, pp. 257-260 (2002), Abstract Only—No Translation.
Koshkin et al.,Tetrahedron, vol. 54, No. 14, pp. 3607-3630 (1998).
Andrew Chin, “On the Preparation and Utilization Isolated and Purified Oligonucleotides”, University of North Carolina School of Law, Mar. 9, 2002.
Acheampong et al., 2002, “Distribution of Brimonidine into Anterior and Posterior Tissues of Monkey, Rabbit, and Rat Eyes,”Drug Metabolism and Distribution, 30(4):421-429.
Beaucage et al., 1992, “Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach,”Tetrahedron, 48(12):2223-2311.
Beaucage et al., 1993, “The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications,”Tetrahedron, 49(28):6123-6194.
Brown et al., 1991, “In Oligonucleotides and Analogues. A Practical Approach,” Oxford: IRL 13-14.
Cao et al., 1998, “Vascular Endothelial Growth Factor C Induces Angiogenesis in vivo,”Proc. Nat. Acad. Sci., 95(24):14389-14394.
Crooke, R.M., 1997, “In Vitro Cellular Uptake, Distribution, and Metabolism of Oligonucleotides,” Antisense Res. and Application 131:103-140.
Dai et al., 2003, “Inhibition of Hypoxia Inducible Factor 1α Causes Oxygen-Independent Cytotoxicity and Induces p53 Independent Apoptosis in Glioblastoma Cells,”Int J. Radiat Oncol Biol Phys., 55(4):1027-1036.
Dass, Crispin R., 2002, “Vehicles for Oligonucleotide Delivery to Tumours,”J Pharm Pharmacol., 54(1):3-27.
Distler et al., 2004, “Physiologic Responses to Hypoxia and Implications for Hypoxia-Inducible Factors in the Pathogenesis of Rheumatoid Arthritis,” Arthritis Rheum., 50(1):10-23.
Heid et al., 1996, “Real time Quantitative PCR,” Genome Res., 6(10):986-994.
Holmes et al., 1991, “Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer,”J. Natl. Cancer Inst., 83(24)1797-1805.
Hoeg, et al., 2002, “Specific down-regulation of hypoxia-inducible factor 1α (HlF1α) in a human glioblastoma cell line by locked nucleic acid (LNA) antisense oli-gonucleotides,”American Association for cancer Research, #4763, vol. 43:962.
Holton et al., 1994, “First Total Synthesis of Taxol. 1. Functionalization of the B Ring,”J. Am. Chem. Soc., 116(4):1597-1598.
Kang et al., 2001, “An Antisense Oligonucleotide That Inhibits the Expression of Hypoxia-Inducible Factor-1α Alters Hypoxia-Induced Changes in Proliferation and Viability of Human Cardiac Fibroblasts,”Basic Science/Schientific Sessions, II-57:274.
Kohn et al., 1994, “Dose-Intense Taxol: High Response Rate in Patients With Platinum-Resistant Recurrent Ovarian Cancer,”J. Natl. Cancer Inst., 86(1)18-24.
Leamon et al., 1991, “Delivery of Macromolecules into Living Cells: A Method that Exploits Folate Receptor Endocytosis,”Proc. Nat. Acad. Sci., 88:5572-5576.
Mcguire et al., 1989 “Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms.”Ann. Intern. Med. 111:273-279.
Nicolaou et al., 1994, “Total Synthesis of Taxol,”Nature367:630-634.
Paul et al., 2004, “HIF at the Crossroads Between Ischemia and Carcinogenesis,”J. Cell. Physiol., 200(1):20-30.
Pedersen et al., 2002, “Preparation of LNA Phosphoramidites,” Synthesis 2000(6):802-808.
Poulaki et al., 2003, “Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas,”J. Clin. Endocrinol. Metab. , 88(11):5392-5398.
Poulaki et al., 2004, “Insulin-Like Growth Factor-I Plays a Pathogenetic Role in Diabetic Retinopathy,”Am. J .Pathology, 165(2):457-469.
Shatrov et al., 2003, “Oxidized Low-Density Lipoprotein (oxLDL) Triggers Hypoxia-Inducible Factor-1α (HIF-1α) Accumulation via Redox-Dependent Mechanisms,”Blood, 101(12):4847-4849.
Streilein et al., 1996, “Immunosuppressive Properties of Tissues Obtained from Eyes with Experimentally Manipulated Corneas,”Investigative Ophthalmology&Visual Science, 37(2):413-424.
Sun et al., 2003, “Regression of Solid Tumors by Engineered Overexpression of von Hippel—Lindau Tumor Suppressor Protein and Antisense Hypoxia-Inducible Factor-1α,”Gene Therapy, 10:2081-2089.
Sun, 2001, “Gene Transfer of Antisense Hypoxia Inducible Factor-1α Enhances the Therapeutic Efficacy of Cancer Immunotherapy,”Gene Therapy, 8(8):638-645.
Venetsanakos et al., 2002, “Induction of Tubulogenesis in Telomerase-Immortalized Human Microvascular Endothelial Cells by Glioblastoma Cells,”Exp. Cell. Res., 273(1):21-33.
Wagner et al., 1990, “

Affiliated with

Also associated with

Rating

Oligomeric compounds for the modulation HIF-1α expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligomeric compounds for the modulation HIF-1α expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligomeric compounds for the modulation HIF-1α expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4241145